PEXIVAS, for Plasma Exchange In VASculitis, was the world’s largest clinical trial on ANCA Associated Vasculitis (AAV), with over 700 patients enrolled internationally. After more than seven years, the results are in! Please join Dr. Michael Walsh and Dr. Nader Khalidi as they share the results with you. Don’t miss it!
Saturday, August 25, 2018
10:00 AM St. Joseph’s Healthcare Hamilton
Miller Auditorium, 2nd floor, Juravinski Tower
50 Charlton Avenue East,
Hamilton, Ontario Canada
Registration is Free, but please RSVP!
Contact: Andrea Mazzetti at:
Phone: 905 522-1155 Ext: 35368
Granulomatosis Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), are rare forms of vasculitis within the ANCA Associated Vasculitis (AAV), family of diseases, including GPA, MPA and EGPA. At disease onset, or in the setting of a relapse, a large number of patients may experience severe organ involvement, which can be organ and even life threatening. To control such severe conditions physicians need to quickly establish an AAV diagnosis and then respond immediately with effective treatment. One such option has always been the possible use of plasma exchange in an effort to quickly rid the patients blood of harmful ANCA autoantibodies.
Principal investigators Dr. Michael Walsh, Dr. Peter Merkel and Dr. David Jayne created an international clinical trial to determine the utility of plasma exchange and steroid dosing in patients with severe AAV. Internationally, 704 patients were enrolled in PEXIVAS over 7 years and we now have the results to share with our participants and the Vasculitis community.
Many of our VFC members participated in PEXIVAS and all AAV patients can benefit by increasing their treatment knowledge, and disease understanding, with knowledge of the PEXIVAS study results!. Please join Dr. Walsh and Dr. Khalidi as they “unpack” PEXIVAS and share the valuable results, and shed some light on what’s next in vasculitis research. We look forward to seeing you on August 25, 2018 in Hamilton. There will be time for Q & A.